Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Pre-participation screening of young competitive athletes for prevention of sudden cardiac death 3. The Job Market for 2008-2009: Compensation 4. Renal Artery Stenosis 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesBenefits of Pharmacogenomics in Drug Development-Earlier Launch of Drugs and Less Adverse Events
The Journal of Medical Systems, 04/16/09
Ohashi W et al. - PGx enables earlier launch of a drug with less cost, representing benefit to pharmaceutical companies, patients and public as a whole. Currently, pharmaceutical companies are reluctant to introduce pharmacogenomics (PGx) in their practice, since cost–benefit of PGx is obscure and methodology to use PGx in drug development has not been fully established yet.
Related Articles
Pharmacogenomic perspectives on the management of mood disorders
Psychiatric Bulletin, 10/02/09
Relevance Score: 87%
Pharmacogenomic variations in treatment protocols for childhood acute lymphoblastic leukemia
Pediatric Blood & Cancer, 10/02/09
Relevance Score: 83%
Role of gut microbiota in Crohns disease
Expert Review of Gastroenterology & Hepatology, 10/13/09
Relevance Score: 80%
Lack of Correlation Between Thiazide-Induced Hyperglycemia and Hypokalemia: Subgroup Analysis of Results from the Pharmacogenomic Evaluation of Antihypertensive Responses Study
Pharmacotherapy, 10/07/09
Relevance Score: 80%
Pharmacogenomics: Personalizing Drug Therapy
American Journal of Nursing, 10/01/09
Relevance Score: 80%
Today in Economics of Medicine...keeping you current
Receive free subspecialty "5-minute updates" via email
HHS Gets Advice on Incentive Definitions
HealthDataManagement, 12/16/09
Presidential order targets improper federal payments
American Hospital Association News, 12/15/09
Community safety net
American Hospital Association News, 12/14/09
Sponsor
Article Search
Sponsor
Sponsor